Comparing the effects of sitagliptin and empagliflozin on blood glucose , lipid profiles, blood pressure and body mass index in type2 dibetics patients treated with Metformin

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045959N1

Enrollment

100

Registered

2020-01-19

Start date

2019-11-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus with hyperosmolarity

Interventions

Intervention 1: Intervention group: The first group received 100 mg of sitagliptin daily added to previous dose of metformin for 3 months. Intervention 2: Intervention group: The second group recei

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Treated with metformin or metformin in combination with sulfonylureas HbA1C between 7 and 9 percent.

Exclusion criteria

Exclusion criteria: Having any cardiovascular, inflammatory, autoimmune disease Pregnancy and lactation Active Liver disease Advanced Renal failure

Design outcomes

Primary

Measure	Time frame
Blood Suger. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Systolic and diastolic blood pressure. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Lipid Profile. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weight.	—

Measure

Time frame

Blood Suger. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Systolic and diastolic blood pressure. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Lipid Profile. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weight.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vahideh Sadra

Tabriz University of Medical Sciences

sadra.vahideh@gmail.com+98 41 3334 8939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026